---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-115723"
form_type: "8-K"
ticker: "UTHR"
cik: "0001082554"
company_name: "UNITED THERAPEUTICS Corp"
filed_at: "2026-10-14T11:00:31+00:00"
generated_at: "2026-10-14T11:05:11.397265+00:00"
event_type: "litigation"
sentiment: "positive"
materiality_score: 0.78
calibrated_materiality_score: 0.78
confidence: "high"
source: SEC EDGAR
---

# UT settles Liquidia patent suits: $330.4M inflow, Yutrepia PH-ILD label removal

## Summary
- Liquidia to pay UT $330.4M: $185M within 30 business days for past Yutrepia PH-ILD sales, plus $145.4M in two $72.7M installments due Jan 31 and Apr 30, 2027.
- UT to pay Liquidia $10M to settle the RareGen/Sandoz antitrust case; Liquidia must obtain Sandoz consent to secure dismissal.
- Liquidia must file an FDA amendment stripping the PH-ILD indication from Yutrepia's label, halt PH-ILD promotion/detailing, and end ASCENT PH-ILD trial cohorts.
- Third Circuit on Oct 7, 2026 affirmed UT on antitrust claims, reversed Sandoz's $61.6M breach-of-contract award, and revived the tortious interference claim.
- UT's '327 patent runs to Feb 3, 2042; trade-secret claims against former Liquidia executive Dr. Robert Roscigno survive the settlement.

## SEC filing metadata
- accession: 0001104659-26-115723
- form_type: 8-K
- ticker: UTHR
- cik: 0001082554
- company_name: UNITED THERAPEUTICS Corp
- filed_at: 2026-10-14T11:00:31+00:00
- event_type: litigation
- sentiment: positive
- materiality_score: 0.78
- calibrated_materiality_score: 0.78
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1082554/000110465926115723/0001104659-26-115723-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1082554/000110465926115723/tm2627546d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-115723
- JSON: https://secwatch.observer/filing/0001104659-26-115723.json
- Plain text: https://secwatch.observer/filing/0001104659-26-115723.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.